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Introduction
The post-infarction remodeling of the myocardium is 
a complex phenomenon that activates the main systems of 
homeostasis, in the acute phase of myocardial necrosis and 
is marked by morpho-functional and metabolic changes 
meant to ensure the adaptation of the heart’s contractility 
by reducing the number of sarcomeres. The quality of the 
post-infarction remodeling, defined by structural and geo-
metrical changes in the first 4-6 months from the onset of 
the myocardial infarction (MI) will lately dictate the clinical 
and functional evolution of the patient as well as the major 
advanced cardiovascular events (MACE) rate. It obviously 
depends on a series of factors, but one of the most impor-
tant is the necrosis area, that usually is widespread in the 
case of MI with elevated ST segment (STEMI) due to a to-
tal or subtotal occlusion (>90%) of a large caliber epicardial 
artery, associated with a conclusive inflammatory response. 
MI without ST-segment elevation (NSTEMI), from the 
physiological point of view, remains an intriguing question 
and a challenge for most cardiologists due to the similar in-
hospital mortality percent (5-7%) and even higher at one 
year distance, versus STEMI, despite its specificity of evolu-
tion in the limit of one coronary artery with a total occlu-
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Abstract
Background: Nowadays, the impact of the delayed myocardial revascularization (DMR) (>72h) in patients with myocardium infarction without ST-
segment elevation (NSTEMI) having either intermediate or low cardiovascular risk (ILCR) on quality of post-infarction myocardial remodeling is not 
well established. Aim of the study: The comparative evaluation of cardiac functional recovery of NSTEMI patients undergoing either revascularization 
<72h or DMR (72h–30 days) in a follow-up of 6 months.
Material and methods: The study was realized in 2 homogenic series of NSTEMI patients with ILCR exposed to revascularization: <72h (control) or to 
DMR (72h–30 days). The echocardiographic and physical test indices were registered at the 2nd day since revascularization and after 6 months.
Results: The increasing ratio of ejection fraction was significantly higher in patients with DMR compared to control (5.24% vs 1.73%). Likewise, the 
contractility ability of left ventricle improved better, proven by systolic volume diminution, lower value of akinetic areas, and less patients with class III 
of heart failure according to New York Heart Association (4 vs 29%). More than that, DMR was associated with higher physical endurance.
Conclusions: NSTEMI patients with ILCR exposed to delayed myocardial revascularization (72h–30 days) had a better post-infarction recovery after 6 
months according to dynamics of echocardiographic and physical tolerance indices in comparison with patients revascularized <72h.
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sion just in ⅓ of cases but with a better distal collateraliza-
tion than STEMI. In the rest, when the coronary occlusion 
is <50%, pathogenetically important, is attributed the role 
of microcirculatory coronary dysfunction, where the sub-
endocardial coronary arteriola (<200 mkm) manifests a 
prothrombotic status, increased by the lasting spasm due to 
endothelial dysfunction.
In STEMI, the revascularization time of the “culprit” ar-
tery is a decisive factor for the prognosis of evolution post 
MI, the optimal accepted window is between 6 and 12 hours 
from the onset of the myocardial necrosis. 
For NSTEMI, the European Society of Cardiology (ESC) 
guidelines recommendations regarding the timing of the in-
vasive treatment are estimated through the 2 scores: Global 
Registry of Acute Coronary Events (GRACE) score and 
Thrombolysis In Myocardial Infarction (TIMI) score. In pa-
tients with high and very high cardiovascular risk, primary 
reperfusion is recommended at the distance of 2 and 24h 
respectively from the MI onset [1]. In patients with mode-
rate or low cardiovascular risk (ILCR), the ESC guidelines 
recommend applying the invasive strategy in the first 72h 
from the establishment of NSTEMI diagnostic, and in case 
of the impossibility to perform the invasive treatment lo-
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cally, the patient should be transferred to a medical center 
with interventional cardiology [2].
Our experience reveals the existence in the Republic of 
Moldova of a large number of patients eligible to this rec-
ommendation, mainly due to the newly installed social re-
strictions because of COVID-19 pandemic, that postpones 
the myocardial reperfusion even to 30 days. 
It is important to emphasize, in this context, the impact 
of the delayed angioplasty on the prognosis of post MI evo-
lution at distance in contiguity with the estimation of the 
character of the morpho-functional remodeling of the myo-
cardium, functional class of heart failure according to New 
York Heart Association (NYHA) as well as on MACE rate. 
Aim of the study: the comparative assessment of the ef-
fects of reperfusion <72 h and delayed reperfusion (72h–30 
days), on echocardiographic parameters and physical en-
durance in NSTEMI patients at the 6 months distance. 
Material and methods
The study was realized on two groups of NSTEMI pa-
tients with GRACE score <140 (intermediate and low car-
diovascular risk), created depending on the angioplasty time:
•	 Group 1, control series (126 patients) revascularized 
<72 h;
•	 Group 2 (126 patients) revascularized in the time be-
tween 72h–30 days.
Both groups were considered homogeneous regarding 
the age, gender, the onset of comorbidities symptoms (hy-
pertension, diabetes mellitus) and other cardiac risk factors 
(tab. 1).
Patients included in the study were investigated in 
the Institute of Cardiology and in the polyvalent hospital 
NOVAMED. The NSTEMI diagnostic was established on 
the base of the clinical, electrocardiographic, echocardio-
graphic and enzymatic criteria: (i) the onset of symptoms 
of acute myocardial ischemia lasting more than 20 minu-
tes, (ii) ST-segment depression more than 1.0 mm and/or 
T-wave changes in more than 2 leads on ECG and/or evi-
dence of loss of viable myocardium or new regional wall 
motion abnormality and (iii) increase of cardiac biomarkers 
(CK-MB and cardiac Troponins TnT).
GRACE score was calculated via the standard formula, 
taking into consideration the age, heart rate (HR), systolic 
blood pressure (SBP), creatinine, ST-segment deviation on 
ECG, abnormal cardiac enzymes and history of cardiac ar-
rest.
Exclusion criteria were:
- High and very high cardiovascular risk;




- Coronary stenosis that caused the infarct < 50% and 
FFR (Fractional Flow Reserve) > 0.80;
- The presence of stenosis > 75% on other vases than 
the one causing the MI;
- History of CABG (coronary artery bypass surgery) or 
PCI (Percutaneous Coronary Intervention);
- Significant valve disease (III-IV degree of insufficien-
cy, moderate or severe stenosis);
- Diffuse LV (left ventricle) hypokinesis on ECHO 
(echocardiography);
- Severe renal failure.
The following examinations were done at admission and 
at a 6 months interval post MI:
Registration of ECG in 12 leads at rest, using the elec-
trocardiographic device “CARDIOLINE AR1200adv” 
(Cardioline S.p.A, Italy) repeated three times: at admission, 
the day after revascularization and at a 6 months distance.
Transthoracic echocardiography (ECHO), realized using 
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the device “PHILIPS Hd11 Xe” (Koninklijke Philips N.V., 
Holland) in M, B and Doppler mode with a 2.0-2.5 mHz 
transducer. The functional and geometrical parameters re-
garding structural and functional remodeling were estimated. 
The stress test was performed using the cycloergomet-
ric device (CEM) “CARDIOLINE cube stress” (Cardioline 
S.p.A, Italy) through the continuous method, pedaling 
speed was 60 rotations per minute, starting from 25 Wt, and 
every step was taking 2 minutes. ECG, HR and SBP were 
constantly monitored. At each step the load was increased 
by 25 Wt. 
The criteria for stopping the test were:
- Reaching the target criteria, 85% from the maximal 
HR (220 – age in years);
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Hight 170.806±0.281 170.810±0.412 170.802±0.385 >0.05
Weight 77.579±0.618 78.786±0.895 76.373±0.843 >0.05
Body weight index 26.537±0.173 26.940±0.261 26.133±0.222 <0.05
Systolic blood pressure 134.786±1.310 134.460±1.909 135.111±1.803 >0.05
Diastolic blood pressure 81.710±0.751 80.952±1.069 82.468±1.056 >0.05
Heart rate 75.087±0.809 76.984±1.109 73.190±1.158 <0.05
- A strong angina seizure;
- Severe dyspnea;
- Ischemic changes on ECG;
- Set of rhythm abnormalities (frequent extrasystole, 
atrial fibrillation, etc.);
- Lowering BP less the initial one or elevation more 
than 230/130 mm Hg;
- Claudication – ischemic pain in the inferior extremi-
ties;
The test was considered positive in the case when the el-
evation or depression of ST segment > 1 mm at 0.08 sec from 
the j point was registered, compared with the ECG at rest.
The coronarography was conducted in the catheteriza-
tion laboratories in the Institute of Cardiology and in the 
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low 49%, that associated with elevated left ventricular end 
diastolic volume (LVEDV) that exceeded on average 144 
ml. Interventricular septal wall (IVSW) and left ventricu-
lar posterior wall (LVPW) thickness, that are considered an 
important index in appreciation of myocardial hypertrophy 
degree, registered values above 11 mm and 10 mm respec-
tively for both groups. 
Except for the rate of severe stenosis and total occlusions 
in the second group versus the first group, data obtained 
during coronarography are similar (tab. 3).
Table 3.  Coronarography data of the nSTEMI patients
Index Group 1 Group 2 p
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polyvalent hospital NOVAMED, using the device General 
Electric INNOVA and Siemens “Artis One”. 
Depending on the degree of stenosis, the coronary le-
sions were divided in (1) insignificant lesions (25%); mod-
erate (25-50%); moderate-severe (51-75%); severe (76-
90%); critical (91-99%) and total occlusion (100%). In the 
case of severe, critical and total occlusion lesions feasibility 
of collateralization was estimated.
After revascularization and stenting the “culprit” artery, 
on the final flow was applied the TIMI system score and 
myocardial “blush” (MBG – Myocardial Blush Grade).
Optical Coherence Tomography (OCT) was realized 
with the “Saint Jude Medical” device, model “ILUMIEN” 
just in the case of those patients whose morphologic pattern 
couldn’t be appreciated through coronary angiography. 
Fractional flow reserve (FFR) was estimated with the 
“Saint Jude Medical” device, model “ILUMIEN” in those pa-
tients who were suspected to have abnormality in coronary 
microcirculation, as a result of a moderate coronary stenosis 
diagnosed during coronary angiography. 
Laboratory investigations have included a large specter 
of circulating markers regarding: irreversible cellular le-
sions, dyslipidemia, endothelial dysfunction, systemic in-
flammation, hyperglycemia, hemostasis, etc.
The angioplasty was realized, using 2 types of stents: bare 
metal stent (BMS) and drug eluting stent (DES). The diam-
eter of the used stents was in the range from 2.25 mm to 5 
mm, while the length between 8 mm and 48 mm.
For the statistical processing of the numerical material, 
were used the accepted biostatistical maneuvers: t-Student 
index (comparison of averages in 2 groups), ANOVA (com-
parison of averages in 3 groups), method of variational 
analysis, correlation, χ2 index (comparison of nonparamet-
ric variables), Pearson correlation coefficient, U-Fischer cri-
terion. Statistically significant in all methods of analysis was 
considered the value p <0.05.
Results
The echocardiographic data from NSTEMI patients es-
timated on the 2nd day after angioplasty are similar in both 
groups (without significant discrepancy) and prove the im-
minent morphofunctional pattern of failed heart (tab. 2).
The ejection fraction was average in both groups, be-
Table 2.  Main echocardiographic parameters from nSTEMI patients on the 2nd day after revascula
Parameters Group 1 Group 2 p
LV diastolic diameter (mm) 53.556±0.475 52.437±0.507 >0.05
LV diastolic volume (ml) 148.341±2.653 144.016±2.240 >0.05
LV systolic diameter (mm) 36.762±0.579 35.683±0.550 >0.05
LV systolic volume (ml) 75.294±2.055 70.627±1.773 >0.05
Interventricular septal wall (mm) 11.500±0.154 11.849±0.150 >0.05
LV posterior wall (mm) 10.274±0.090 10.389±0.128 >0.05
Ejection fraction (EF) (%) 47.063±0.785 48.754±0.748 >0.05
Normokinetic pattern              No 112 (88.9%) 108 (85.7%) >0.05
Normokinetic pattern             Yes 14 (11.1%) 18 (14.3%) >0.05
Relaxation disorders               Yes 118 (93.7%) 120 (95.2%) >0.05
Relaxation disorders                No 118 (93.7%) 120 (95.2%) >0.05
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One of the notable points for estimating the quality of 
post-myocardial infarction remodeling is the severity of 
heart failure. It is remarkable that a higher rate of patients 
with NYHA II in group 2 compared to group 1 at a 6 months 
interval after angioplasty (66.7 vs 52.4%) while the rate of 
NYHA III, on the contrary is significantly lower (4 vs 29%). 
This observation indicates a better functional heart re-
covery in NSTEMI patients treated with postponed revas-
cularization, at 72 h. In this aspect, the dynamics of echo-
cardiographic indices attested at a distance of 6 months after 
revascularization is also intelligible (tab. 4).
It is important to mention a more significant increase of 
EF in group 2 versus group 1 (5.24% vs 1.73%) that is also 
associated with a notable LV contractility recovery visible 
through a 5.56% decrease of LV end systolic volume mean-
while it increased by 1.05% in the control group. A similar 
dynamic was observed regarding LV systolic diameter. 
Table 4.  Relative deviations (%) of echocardiographic parameters among a period of 6 months
Parameters
Group 1 Group 2
P
M m p M m p
Left atrium diameter +0.484 0.191 <0.05 -0.341 0.136 <0.05 <0.01
LV diastolic diameter +1.097 0.210 <0.001 +1.103 0.434 <0.05 >0.05
LVEDV +2.742 1.028 <0.01 +0.944 1.128 >0.05 >0.05
LV systolic diameter +0.508 0.302 >0.05 -1.960 0.243 <0.001 <0.001
LV end systolic volume +1.048 1.080 >0.05 -5.556 0.615 <0.001 <0.001
IVSW -0.121 0.09 >0.05 -0.159 0.05 <0.01 >0.05
LVPW -0.085 0.06 >0.05 +0.071 0.05 >0.05 >0.05
EF +1.734 0.58 <0.01 +5.238 0.36 <0.001 <0.001
Right ventricle diameter -0.177 0.18 >0.05 -0.683 0.23 <0.01 >0.05
Right atrium +0.637 0.24 <0.01 -0.175 0.19 >0.05 <0.01
Pulmonary systolic arterial pressure -7.113 0.65 <0.001 -9.873 0.48 <0.001 <0.01
hypokinetic areas +1.135 0.12 <0.001 +1.397 0.12 <0.001 >0.05
akinetic areas  -0.095 0.1 >0.05 -0.159 0.07 <0.05 <0.05
dyskinetic areas -0.325 0.09 <0.001 -0.04 0.04 >0.05 <0.01
areas involved in the aneurysm -0.294 0.08 <0.001 -0.048 0.05 >0.05 <0.01
Table 5.  The results of the stress test at nSTEMI patients 6 months after revascularization 
Parameter General group Group 1 Group 2 p
Initial systolic blood pressure (SBP) 124.627±0.735 124.202±1.120 125.032±0.962 >0.05
Initial diastolic blood pressure (DBP) 70.656±0.591 71.639±0.889 69.720±0.777 >0.05
Initial heart rate (HR), 1/min 67.545±0.402 68.151±0.613 66.968±0.520 >0.05
Max intensity effort, Wt 105.430±1.710 99.370±2.487 111.200±2.244 <0.001
Total time of physical effort, min 8.898±0.159 8.319±0.234 9.448±0.205 <0.001
Max SBP at effort, mm Hg 187.705±1.120 186.261±1.708 189.080±1.457 >0.05
Max DBP at effort, mm Hg 101.631±0.771 100.504±1.073 102.704±1.100 >0.05
Max HR, 1/min 134.377±1.379 131.773±2.187 136.856±1.686 >0.05
Reached target HR, 1/min                No
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From a pathophysiologic point of view, the decrease of 
right ventricle (RV) dimension in association with reduction 
of pulmonary pressure index in both groups is important. 
Regarding the dynamics of the kinetic changes of the 
heart in the post-infarction remodeling, the phenomenon 
of diminution of dyskinetic areas, akinetic areas and risk 
areas for aneurysm in both groups are important, that sub-
sequently influences the EF. On the other hand, the sum of 
hypokinetic areas increased to an incremental value similar 
in both groups.
The positive heart changes developed during the post-
infarctional period are followed by an improved tolerance 
to physical effort (tab. 5).
It is worth noting that the intensity of the maximum ef-
fort made by patients in group 2 was considerably higher 
compared to group 1: 111.200±2.244 vs 99.370±2.487 Wt 
(p<0.001). The total effort time also became significantly 
longer, with an average delay of 1.1 min: 9.448±0.205 vs 
8.319±0.234 min (p<0.001). Was documented as well, a 
larger number of patients that reached the aimed HR: 89.6% 
vs 68.9%.
The cumulative benefit of physical endurance in pa-
tients at the end of 6-month period after revascularization 
of NSTEMI, was manifested with high physical tolerance at 
a much higher rate in the case of delayed angioplasty com-
pared to angioplasty in the first 72 hours: 45.6% vs 31.9%.
Summarizing, delayed revascularization in NSTEMI 
patients with intermediate and low cardiovascular risk, ap-
plied at a 72 h- 30 day distance, proved at 6 months a mor-
phofunctional heart remodeling comparable to the pattern 
of imminent revascularization applied in the first 72 hours, 
more than that, some changes are even more conclusive: (1) 
increase of EF, (2) decrease of LVSV and LVSD, (3) the rate 
of  NYHA II patients, (4) maximal exercise intensity, total 
physical effort time, and rate of patients with high tolerance 
to physical effort.
Discussion
The crucial difference in addressing invasive treatment 
of NSTEMI patients with intermediate and low cardiovas-
cular risk calculated by GRACE score (<140) was deter-
mined by the revascularization time: <72h and between 72h 
and 30 days (delayed revascularization). Results obtained at 
a distance of 6 months, on the restoration of ECHO indices 
and tolerance to physical effort, as a reflection of the heart's 
ability of a post-infarction remodeling, proved to be better 
in the case of postponed revascularization. This phenom-
enon reveals new perspectives in the application of angio-
plasty in this type of patients and may basically serve as an 
indispensable maneuver of time variable.
Several plausible hypotheses of exegesis and explanation 
of these benefits exist.
First of all, patients with NSTEMI had an intermedi-
ate and low cardiovascular risk according to GRACE score 
and the coronary stenoses >75% didn’t exist. Likewise, the 
collateral system in the ischemic myocardium zone was 
quite well developed (the phenomenon of distal coronary 
artery recharge on coronary angiography was present in 
65.7% of patients). Revascularization applied during the 
first 72 hours coincides with the peak of the inflammatory 
response, cytokine expression, blood cell infiltration, and 
due to this, the maximum activity of oxidative stress. Thus, 
the expected benefit of revascularization is compromised 
by the detrimental action of these factors. It is well known 
that the maximum expression of neutrophils in the area of 
myocardial necrosis occurs within 24-48 hours, while the 
expression of proinflammatory macrophages (M1) is found 
at maximum proportion in the period 48-72 hours [3].
Second of all, delayed revascularization occurs during 
the period of natural restoration of the intrinsic antioxidant 
potential, after the ischemic impact, and the power of the 
oxygen paradox inherent to revascularization is thus depre-
ciated, especially after 72 hours when the expression of anti-
inflammatory macrophages (M2) increases [4, 5].
Third of all, the traumatic impact of delayed revascular-
ization occurs due to a longer and more consistent meta-
bolic remodeling, its main elements being the expression of 
the growth transformation factor (TGF-β) induced by anti-
inflammatory cytokines, which increases the intracellular 
expression of “heat-shock” proteins, recognized as factors 
in ensuring the resistance of cells to the action of various 
endogenous and exogenous lesions [6, 7].
Another important thing, in the patients of group 2 the 
ratio of atherosclerotic/thrombotic lesions of the “culprit” 
artery was higher than 1. In the group with revasculariza-
tion <72 hours, on the contrary, this ratio was <1. Therefore, 
the prevalence of atherosclerotic paternal coronary lesion is 
a precondition for a better post-procedural evolution of the 
myocardial remodeling process compared to the predilec-
tion of thrombotic paternal. The latter has an increased risk 
of post-procedural thromboembolism and the phenomenon 
of 'low-reflow' or 'non-reflow' during reperfusion, inclusive 
in patients with MI and elevated ST segment [8, 9]. Deep 
embolization affects the subendocardial microcirculation 
and may in the context of «low-reflow» and «non-reflow» 
phenomena trigger the development of the sidereal and hi-
bernated myocardium. This factor may possibly have condi-
tioned higher LVESV values in patients with NSTEMI treat-
ed by revascularization <72 hours at a distance of 6 months.
Altogether, these arrangements may have the signifi-
cance of beneficial preconditions for the cumulative im-
pact of delayed myocardial revascularization in NSTEMI 
patients on post-infarction morphofunctional remodeling 
and clinical evolution.
Another element that should be noticed is that among 
the factors that determined the benefit of delayed revascu-
larization is the presence of a lower rate of patients with to-
tal occlusion of the coronary artery in group of NSTEMI pa-
tients exposed to DMR: 39.7% vs. 48.7%. In the VERDICT 
trial, the rate of NSTEMI patients, in which the coronary 
angiography examination identified total occlusion, reached 
26.6% [10].
Among the caliber trials in which delayed revascular-
ization was applied, the ISAR-COOL study should be men-
tioned, which excelled in an average angioplasty time of 86 
hours and showed benefits similar to our research.
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In the ICTUS study, the analysis of the death rate of 
NSTEMI patients at a distance of 10 years, did not prove 
conclusive benefits for revascularization <72 hours [11].
Finally, the analysis of the obtained results appeals to 
some conceptually and practically significant hypotheses:
• Delayed revascularization of patients with intermedia-
te and low risk NSTEMI caused by total coronary occlusion 
would have a similar benefit to revascularization <72 hours, 
regarding post-infarction morphofunctional remodeling of 
the myocardium.
• In case of delayed revascularization of NSTEMI pa-
tients with intermediate and low cardiovascular risk, caused 
by stenosis <50%, the superiority of efficacy over revascu-
larization <72 hours is plausible. In this context, the prompt 
and accurate diagnosis by use of instrumental markers (e.g. 
Magnetic resonance imaging) is important. Likewise, it is 
opportune the use of veritable circulatory markers of coro-
nary microcirculation disorder responsible for subendocar-
dial infarction, especially when cardiac troponins (TnT and 
TnI) dynamics and ECG outcomes are uncertain. Our expe-
rience based on applying of multi-marker strategy validates 
the predictive value of the markers which refer to the in-
flammatory response, oxidative stress, endothelial dysfunc-
tion and prothrombotic status.
Conclusions
1. In our study, delayed myocardial revascularization (72 
hours - 30 days) applied for treatment of NSTEMI patients 
with intermediate and low cardiovascular risk, had proved 
the superior benefits in concern to clinical-functional evo-
lution at a 6 months follow-up period compared to revascu-
larization <72 hours.
2. The most important traits of delayed myocardial re-
vascularization benefit are: (i) greater increase of EF, (ii) de-
crease in both LV end systolic volume and LV systolic dia-
meter, (iii) increase in the number of patients with NYHA 
II and the reduction of NYHA III cases, as well as physical 
endurance boosting, manifested by double more patients, 
who fulfilled maximal physical endeavor. 
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